Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
Nature Reviews. Cancer|June 2, 2005
Pharmacokinetic variability of anticancer agentsSamir D Undevia, Gonzalo Gomez-Abuin, Mark J RatainJournal of Neuro-Oncology|September 30, 2005
Spinal cord metastasis of a non-neurofibromatosis type-1 malignant peripheral nerve sheath tumor: an unusual manifestation of a rare tumorWilliam S Baek, Peter Pytel, Samir D Undevia, et al.European Journal of Cancer (Oxford, England : 1990)|May 26, 2009
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9Wei Peng Yong, Tae Won Kim, Samir D Undevia, et al.Investigational New Drugs|August 5, 2004
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumorsSamir D Undevia, Nicholas J Vogelzang, Ann M Mauer, et al.Investigational New Drugs|September 15, 2010
A phase I study of continuous infusion cilengitide in patients with solid tumorsPeter H O'Donnell, Samir D Undevia, Walter M Stadler, et al.Clinical Pharmacology and Therapeutics|November 13, 2004
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbitalFederico Innocenti, Samir D Undevia, Jacqueline Ramírez, et al.Investigational New Drugs|May 8, 2015
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumorsMark J Ratain, David Geary, Samir D Undevia, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2009
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatmentMichael L Maitland, Kristen E Kasza, Theodore Karrison, et al.European Journal of Cancer (Oxford, England : 1990)|July 25, 2008
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumoursSamir D Undevia, Federico Innocenti, Jacqueline Ramirez, et al.Pediatric Blood & Cancer|September 23, 2010
The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growthNisha C Kakodkar, Radhika Peddinti, Morris Kletzel, et al.Pageof 2